Pharvaris (PHVS) Assets (2019 - 2026)
Pharvaris' (PHVS) quarterly Assets came in at $304.1 million in Q1 2026, up 16.56% YoY from $260.9 million in Q1 2025, and down 13.33% on a QoQ basis from $350.9 million in Q4 2025.
Analysis
Pharvaris (PHVS) Assets (2019 - 2026) Analysis & Trends
Pharvaris (PHVS) has 8 years of Assets data on file, last reported at $304.1 million in Q1 2026.
- Quarterly Assets rose 16.56% year-over-year to $304.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $304.1 million (up 16.56% YoY) and the FY2025 annual result came in at $340.6 million, up 8.0% from the prior year.
- Assets declined to $304.1 million in Q1 2026, from $350.9 million in the prior quarter.
- In the past five years, Assets ranged from a high of $429.0 million in Q4 2023 to a low of $158.6 million in Q1 2023.
- A 5-year average of $282.0 million and a median of $260.9 million in 2025 frame the typical range for Assets.
- Annual changes were most pronounced in 2024 — Assets jumped 158.58% — and 2025, when it plunged 37.32%.
- Tracing PHVS's Assets over 5 years: stood at $171.1 million in 2022, then surged by 150.67% to $429.0 million in 2023, then fell by 27.42% to $311.4 million in 2024, then advanced by 12.7% to $350.9 million in 2025, then slipped by 13.33% to $304.1 million in 2026.
- The last three Assets figures came in at $304.1 million (Q1 2026), $350.9 million (Q4 2025), and $396.2 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 10.96 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.32 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 9.18 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 5.56 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Pharvaris | 2.10 Bn | 1.73 Bn | 85,072.10 | 382.03 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 382.03 Mn |
| Mar 31, 2026 | 304,145.72 Bn |
| Dec 31, 2025 | 350.91 Mn |
| Sep 30, 2025 | 396.19 Mn |
| Jun 30, 2025 | 237.50 Mn |
| Mar 31, 2025 | 260.93 Mn |
| Dec 31, 2024 | 311.36 Mn |
| Sep 30, 2024 | 343.94 Mn |
| Jun 30, 2024 | 378.90 Mn |
| Mar 31, 2024 | 410.20 Mn |
| Dec 31, 2023 | 428.97 Mn |
| Sep 30, 2023 | 184.34 Mn |
| Jun 30, 2023 | 206.62 Mn |
| Mar 31, 2023 | 158.64 Mn |
| Dec 31, 2022 | 171.13 Mn |
| Sep 30, 2022 | 204.66 Mn |
| Jun 30, 2022 | 220.61 Mn |
| Mar 31, 2022 | 225.74 Mn |
| Dec 31, 2021 | 242.62 Mn |
| Sep 30, 2021 | 263.09 Mn |